Skip to main content

Table 1 Patient’s demographic characteristics and vitreous hemorrhage score at baseline

From: Intravitreal bevacizumab (IVB) versus IVB in combination with pars plana vitrectomy for vitreous hemorrhage secondary to proliferative diabetic retinopathy: a randomized clinical trial

 

Group A

Group B

p

Age (Mean ± SD)

63.66 ± 8.16

64.03 ± 11.24

0.8475

Gender

15 M//20 F

18 M//17 F

0.1470

SAH (n)

34

34

0.5072

Lens Status

(phakic / pseudophakic)

28 (80.0)/7 (20.0)

31 (88.58)/4 (11.42)

 

Previous PRP (%)

16 (45.7)

13 (37.1)

0.4667

Partial PRP *

8 (22.85)

9 (25.8)

Complete PRP

8 (22.85)

5 (14.3)

Baseline VH Score (%)

 

0.3735

Grade 1

3 (8.6)

1 (2.9)

Grade 2

14 (40)

11 (31.4)

Grade 3

18 (51.4)

23 (65.7)

  1. SAH systemic arterial hypertension, M male, F female, PRP panretinal photocoagulation, VH vitreous hemorrhage
  2. * ≤ 3 quadrants of full scatter PRP